Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost

By Amira McKee

Amgen posted higher revenue in the fourth quarter on double-digit product volume growth.

The biotechnology company on Tuesday reported a fourth-quarter profit of $1.33 billion, or $2.45 per share, compared with a profit of $627 million, or $1.16 per share, a year earlier. The company attributed its 111% boost in earnings to higher revenue and lower net unrealized losses on equity investments.

Adjusted earnings were $5.29 per share. Analysts polled by FactSet expected $4.51 per share.

Revenue rose 9% to $9.87 billion, ahead of the $9.47 billion projected by Wall Street, according to FactSet.

Product sales grew 7%, led by 10% growth in product volume. The gains were partially offset by a 4% decrease in selling price.

For 2026, Amgen forecasts revenue of $37.0 billion to $38.4 billion and adjusted earnings of $21.60 to $23.00 per share. Analysts are projecting revenue of $37.19 billion and adjusted earnings of $20.63 per share, according to FactSet.

The results follow Amgen's October kickoff of its direct-to-patient program designed to lower the cost of drugs. The program, called AmgenNow, is in response to the White House's call to reduce prescription drug prices for U.S. consumers.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

February 03, 2026 16:49 ET (21:49 GMT)